NCT04677881

Brief Summary

Dietary fiber is well known to have health promoting effects, including reduced blood glucose and cholesterol levels. Bread is the most important source of dietary fiber in the Norwegian diet. Production of bread has changed from the traditionally use of sourdough, to yeast (Saccharomyces cerevisiae) as the dominating leavening agent in modern industrial production. Sourdough naturally contains bacteria, and through the fermentation process these bacteria release several components that are not found in modern bread using yeast. It has been shown that sourdough may have positive health effects, including on blood glucose regulation. The aim of the project is to investigate if intake of sourdough may give positive health effects compared to beard with yeast.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2020

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

November 26, 2020

Completed
24 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 21, 2020

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

May 12, 2021

Status Verified

October 1, 2020

Enrollment Period

4 months

First QC Date

November 26, 2020

Last Update Submit

May 11, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Gastrointestinal Symptom Rating Scale-irritable bowl syndrome (GSRS-IBS)

    GSRS-IBS analysis after intervention with bread baked with yeast versus sourdough with the following response scale: 1 (no discomfort at all) to 7 (very severe discomfort)

    5 weeks

Secondary Outcomes (4)

  • Bristol stool chart (BSC)

    5 weeks

  • Blood C-peptide, total cholesterol, triglycerides, fatty acid profile, and short chain fatty acids

    5 weeks

  • Feces microbiota analysis performed with Bio-Me's Precision Microbiome Profiling platform (PMP™)

    5 weeks

  • Iron, selenium and zinc in blood

    5 weeks

Study Arms (2)

Wholegrain bread with yeast

PLACEBO COMPARATOR

The control group will be given min. 5 slices of bread baked with yeast per day.

Other: Intervention group

Wholegrain bread with sourdough

EXPERIMENTAL

The experimental group will be given min. 5 slices of bread baked with sourdough per day.

Other: Intervention group

Interventions

intervention group: bread with sourdough control group: bread with yeast

Wholegrain bread with sourdoughWholegrain bread with yeast

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • healthy adults who restrict their intake of bread due to stomach ache.

You may not qualify if:

  • Chronic metabolic diseases, such as diabetes type 1 or 2, cardiovascular diseases and cancer last 6 months
  • Gut diseases, including Chron's disease, ulcers colitis
  • Food allergies or intolerance
  • Pregnant and/or lactating
  • Smokers
  • BMI \<18,5 and \>27 kg/m2
  • Planed weight reduction and/or ± 5% weight change last 3 months
  • Blood donor last 2 months and during the study period
  • Not willing to quit taking dietary supplements, including probiotics, cod liver oil etc., 4 weeks prior to study start and during the study
  • Use of antibiotics \<3 months prior to study start and during the study
  • Alcohol intake \>40 g/day
  • Hormone treatment (except contraceptives)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vibeke Telle-Hansen

Oslo, 0130, Norway

Location

Study Officials

  • Vibeke Telle-Hansen, PhD

    Oslo and Akershus University College

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 26, 2020

First Posted

December 21, 2020

Study Start

September 1, 2020

Primary Completion

December 20, 2020

Study Completion

December 31, 2020

Last Updated

May 12, 2021

Record last verified: 2020-10

Data Sharing

IPD Sharing
Will not share

Locations